In specific settings, DPP4 inhibitors enhance antitumor immunity by preserving the functional integrity of chemokines, such as CXCL10 (15), whereas DPP4 inhibition sustains the ability of CXCL10 to recruit CXCR3-expressing lymphocytes to the tumor parenchyma by preventing its enzymatic truncation, thereby improving immune cell trafficking and amplifying the efficacy of immunotherapies, including ICIs. Here, CXCL10 is linked to neoplasm.